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Abstract  
Metabolic bone diseases comprise a diverse group of disorders characterized by alterations in skeletal 
homeostasis, and are often associated with abnormal circulating concentrations of calcium, phosphate 
or vitamin D metabolites. These diseases commonly have a genetic basis and represent either a 
monogenic disorder due a germline or somatic single gene mutation, or an oligogenic or polygenic 
disorder that involves variants in more than one gene. Germline single gene mutations causing 
Mendelian diseases typically have a high penetrance, whereas the genetic variations causing 
oligogenic or polygenic disorders are each associated with smaller effects with additional 
contributions from environmental factors. Recognition of familial monogenic disorders is of clinical 
importance to facilitate timely investigations and management of the patient and any affected 
relatives. The diagnosis of monogenic metabolic bone disease requires careful clinical evaluation of 
the large diversity of symptoms and signs associated with these disorders. Thus, the clinician must 
pursue a systematic approach beginning with a detailed history and physical examination, followed by 
appropriate laboratory and skeletal imaging evaluations. Finally, the clinician must understand the 
increasing number and complexity of molecular genetic tests available to ensure their appropriate use 
and interpretation.  
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Introduction 
 
Metabolic bone diseases represent a diverse group of skeletal conditions characterized by alterations 
in bone cell activity, bone matrix proteins, or systemic mineral homeostasis (Table 1) [1, 2]. Many 
metabolic bone diseases have a genetic basis, which may be a germline single gene abnormality (i.e. a 
monogenic or Mendelian disorder), a somatic single gene defect (i.e. a post-zygotic mosaic disorder) 
or involve several genetic variants (i.e. oligogenic or polygenic disorders) [3]. Genetic mutations 
causing Mendelian diseases usually have a large effect (i.e. penetrance), whereas oligogenic or 
polygenic disorders are associated with several genetic variations, each of which may have smaller 
effects with greater or smaller contributions from environmental factors (i.e. multifactorial disorders) 
[3]. Whilst many monogenic disorders result from rare mutations affecting the coding sequence of the 
responsible gene, the majority of common genetic variants identified in association with polygenic 
traits are located in non-coding regions, usually in proximity to candidate genes implicated in the 
respective disorders [4]. Furthermore, there is substantial overlap between the genes responsible for 
monogenic skeletal diseases and those contributing to polygenic bone phenotypes. The elucidation of 
these loci has provided insights into the molecular pathogenesis of skeletal disease, and highlighted 
novel therapeutic targets [5-7]. This review discusses the genetics of metabolic bone diseases, and 
outlines the clinical and genetic approach to evaluating these disorders. 
 
Genetics of metabolic bone diseases 
 
Inheritance 
Metabolic bone diseases may be caused by single-gene mutations or represent digenic or complex 
polygenic traits [1, 3, 8]. Inheritance of monogenic diseases occurs as one of six traits: autosomal 
dominant (e.g. familial hypocalciuric hypercalcaemia (FHH) due to mutations of the calcium-sensing 
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receptor (CaS receptor) signalling pathway [9]); autosomal recessive (e.g. vitamin D-dependent 
rickets types 1 and 2 from mutations of the renal 1-hydroxylase (CYP27B1) and vitamin D receptor 
(VDR) genes, respectively [10]); X-linked recessive (e.g. Dent’s disease involving chloride channel 5 
(CLC-5) [11]); X-linked dominant (e.g. X-linked hypophosphatemic (XLH) rickets from mutations of 
a phosphate endopeptidase on the X chromosome (PHEX) gene [10]); Y-linked (e.g. azoospermia and 
oligospermia) [12]; and non-Mendelian mitochondrial defects (e.g. hypoparathyroidism in Kearns-
Sayre syndrome and mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes 
(MELAS) syndrome) [13, 14]. Monogenic metabolic bone diseases may also be caused by sporadic 
postzygotic mosaicism (e.g. McCune-Albright syndrome (MAS)) (Table 1) [15]. Digenic inheritance 
has been reported in a family with hereditary hypophosphataemic rickets with hypercalciuria 
(HHRH), who harbor heterozygous mutations of the SLC34A1 and SLC34A3 genes, encoding the 
renal sodium-phosphate co-transporters type 2a and 2c, respectively [8]. The major metabolic bone 
disorder representing a complex polygenic trait is osteoporosis, and >200 loci have been associated 
with this common disorder [16, 17]. However, the majority of loci for osteoporosis likely remain to be 
elucidated. Osteoporosis may rarely occur as a monogenic condition e.g. X-linked osteoporosis due to 
mutations of the Plastin 3 (PLS3) gene [18], or early-onset osteoporosis due to heterozygous 
mutations of the Wnt family member 1 (WNT1) gene (Table 1) [19]. 
 
Genetic heterogeneity  
Many phenotypically similar metabolic bone disorders are caused by mutations in a variety of 
different genes. For example, 85-90% of osteogenesis imperfecta (OI) cases are due to mutations in 
the genes encoding type 1 collagen (i.e. COL1A1 and COL1A2) [20], with the remaining 10-15% of 
OI cases being caused by mutations affecting genes involved in post-translational processing of 
collagen (e.g. cartilage-associated protein (CRTAP) [21], osteoblast differentiation and function (e.g. 
WNT1) [19, 22], or bone mineralization (e.g. interferon induced transmembrane protein 5 (IFITM5) 
(Table 1) [23, 24]. Similarly, hypophosphataemic rickets may be caused by mutations of genes 
encoding phosphatonins like fibroblast growth factor-23 (FGF-23), or osteoblast and osteocyte 
proteins that mediate the expression and secretion of FGF-23 (e.g. PHEX, dentin matrix protein 1 
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(DMP1), and ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1)) [25-28], or by mutations 
affecting renal sodium phosphate co-transporters (e.g. SLC34A3) (Table 1) [29, 30]. In addition, FHH, 
which is a disorder of extracellular calcium homeostasis, has been shown to comprise three types, 
which are caused by germline loss-of-function mutations affecting the CaS receptor, G-protein 
subunit-11 (G11), and adaptor-related protein complex-2 -subunit (AP2), respectively (Table 1)  
[31-33]. 
Mutations within a single gene may give rise to seemingly distinctive skeletal phenotypes 
[(e.g. familial expansile osteolysis (FEO), expansile skeletal hyperphosphatasia (ESH), and early-
onset familial Paget’s disease of bone (PDB)], which are rapid remodeling skeletal disorders arising 
from mutations in the signal peptide of receptor activator of NF-κB (RANK) [34, 35]. In some 
metabolic bone diseases, the severity may be determined by mutant allele dosage and whether a 
mutation is carried in the heterozygous or homozygous state. For example, the severe perinatal and 
infantile forms of hypophosphatasia, an inborn-error-of-metabolism characterized by alkaline 
phosphatase (ALP) deficiency, are inherited in an autosomal recessive manner, whilst later-onset and 
more mild forms are typically inherited in an autosomal dominant fashion (Table 1) [36]. Moreover, 
some disorders of mineral metabolism are caused by loss- or gain-of-function mutations affecting the 
same gene. Thus, loss-of-function CaS receptor mutations cause FHH or neonatal severe 
hyperparathyroidism (NSHPT), whereas gain-of-function CaS receptor mutations cause autosomal 
dominant hypocalcaemia (ADH) or Bartter syndrome type V [31, 37, 38]. Furthermore, parental 
imprinting, which results in non-Mendelian inheritance of a monogenic disorder, may influence the 
phenotypic consequences of a specific mutation. For example, maternally inherited inactivating 
coding-region mutations of G-protein subunit αs (Gαs), which is encoded by the GNAS gene, cause 
pseudohypoparathyroidism type 1a (PHP1a), which is characterised by PTH resistance together with 
Albright’s hereditary osteodystrophy (AHO) [39]; whereas, paternally inherited inactivating coding-
region GNAS mutations cause pseudopseudohypoparathyroidism (PPHP), which is characterised by 
AHO without PTH resistance (Table 1)  [39]. The phenotype of MAS, which is caused by somatic 
activating Gαs mutations, is also dependent on parental imprinting, with acromegaly occurring in 
MAS patients who harbour mutations affecting the maternal Gαs allele [40]. Given this apparent 
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genetic/phenotypic complexity despite genetic “homogeneity”, establishing the genetic cause can be 
challenging for the evaluation of patients and family members with bone and mineral disorders. 
 
Molecular insights from monogenic and polygenic diseases 
Classical gene-discovery approaches for monogenic disorders have involved studying affected 
kindreds for co-segregation with polymorphic genetic markers to define the chromosomal location, 
followed by DNA sequence analysis of genes located within the candidate region [3]. This approach 
has been superseded by whole-exome and whole-genome sequence analysis of affected patients or 
kindreds [41, 42]. In contrast, the genetic investigation of complex polygenic disorders such as 
osteoporosis has utilized genome-wide association studies (GWAS), which involve large populations 
of cases and controls [5, 6, 16, 17]. Such studies typically involve direct or imputed genotyping of 
large numbers of common (e.g. minor allele frequency >5%) and infrequent (e.g. minor allele 
frequency 1-5%) single nucleotide polymorphisms/variants (SNPs/SNVs) to identify genetic loci 
enriched for the trait [3, 43]. The genetic investigation of monogenic diseases has provided a 
fundamental understanding of the molecular regulation of bone mass and maintenance of skeletal 
microarchitecture. For example, studies of mutations affecting several Wnt pathway components have 
demonstrated that Wnt signaling plays a key anabolic role in the skeleton (Figure 1) [44, 45]. Thus, 
autosomal-recessive loss-of-function mutations of the LRP5 gene, which encodes a key Wnt co-
receptor (Figure 1), result in osteoporosis-pseudoglioma syndrome, which is characterized by severe 
juvenile osteoporosis and congenital or childhood-onset blindness [46]. In contrast, heterozygous 
activating mutations in LRP5 [47] and LRP6 [48], which encode the cognate co-receptors LRP5 and 
LRP6, respectively, both lead to autosomal dominant high bone mass. Additionally, individuals with 
autosomal recessive loss-of-function mutations of the Wnt-β-catenin inhibitor sclerostin (SOST) 
manifest sclerosteosis, type 1, which is characterized by progressive bone overgrowth throughout life 
[49, 50]; whilst patients harbouring a homozygous 52kb deletion containing an enhancer element 
downstream of the SOST gene develop van Buchem disease, which has a similar but milder skeletal 
phenotype compared to sclerosteosis, type 1 [51, 52]. Moreover, bi-allelic loss-of-function mutations 
of WNT1 have been shown to cause an autosomal recessive form of OI, whilst heterozygous carriers 
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of such WNT1 missense mutations develop autosomal dominant early-onset osteoporosis (Figure 1) 
[19, 53]. Additionally, bi-allelic truncating mutations in secreted frizzled-related protein 4 (sFRP-4) 
(Figure 1), which encodes a soluble Wnt inhibitor, have been reported in patients with Pyle’s disease, 
a disorder characterized by cortical bone thinning, limb deformity and fracture [54]. These key roles 
for Wnt signalling in bone biology are supported by the findings from GWAS studies, which have 
identified that many Wnt pathway components (>15 genes), including LRP5 and SOST are candidate 
genes for bone mineral density (BMD) [16, 17], and that WNT16 is a key determinant of cortical bone 
strength [55, 56].
 
 
 
Application of genetic discoveries to the development of targeted therapies 
A key aim of the genetic characterization of metabolic bone disorders has been to identify genes, 
molecules and pathways that may be targeted therapeutically. Thus, the identification of the bone cell 
OPG/RANKL/RANK/NF-κB signalling pathway led to the development of the monoclonal antibody 
denosumab, which blocks RANK ligand (RANKL), thereby inhibiting osteoclast-mediated bone 
resorption [5]. Denosumab is now widely used for the treatment of osteoporosis as it significantly 
reduces fracture risk in women with postmenopausal osteoporosis [57]. The multinational approval in 
2015 of the bone-targeted enzyme-replacement biologic asfotase alfa to treat hypophosphatasia has 
emphasized the importance of determining the genetic and molecular basis for a metabolic bone 
disease [36]. The identification that PHEX mutations cause FGF-23 excess, which in turn is 
responsible for the phosphate wasting in XLH [58, 59], has led to the approval in 2018 of burosumab, 
which is an anti-FGF-23 monoclonal antibody, for the treatment of XLH rickets. Burosumab has been 
shown to improve serum phosphate concentrations and decrease the severity of rickets in children 
with XLH [60]. Assessing treatment response according to the genetic aetiology has been investigated 
in patients with early-onset low-turnover osteoporosis due to WNT1 or PLS3 mutations who were 
shown to respond to teriparatide therapy [61]. Now, several drugs in development are directed at the 
Wnt pathway. This includes anti-sclerostin antibodies (e.g. romosozumab), which increase bone 
formation whilst inhibiting bone resorption [62]. An evaluation of romosozumab in phase 3 clinical 
trials has shown that it is a potent bone anabolic agent for postmenopausal osteoporosis [63, 64]. 
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Clinical approach to the patient with a metabolic bone disease 
 
Medical history and physical examination 
The diagnosis of genetic forms of metabolic bone diseases begins by acquiring information from the 
patient’s medical history and physical examination [3]. The “history of present illness” provides 
critical clues concerning aetiology, pathogenesis and prognosis, as well as guiding diagnosis and 
therapy. Establishing whether the signs and symptoms have been lifelong, or begun recently may 
prompt different diagnostic considerations and interventions. Thus, lifelong fractures which have 
occurred following minor trauma may suggest a diagnosis of OI [20]. Whereas, the combined 
occurrence of fractures and renal calculi in early adulthood may potentially be a presenting feature of 
primary hyperparathyroidism caused by the multiple endocrine neoplasia (MEN) type 1 syndrome 
[65]. Moreover, it is important to review prior medical records, radiographs, and other investigations 
such as the results of plasma and urinary biochemistry, to aid diagnosis and prognostication [3]. 
Physical assessment should include: measurement of body proportions, limb lengths and head 
circumference; an examination of the spine for scoliosis or kyphosis; and joint hypermobility with a 
determination of the Beighton  score [66]. Physical examination can show a variety of findings for 
diagnosis e.g. : blue or gray sclerae found in OI; café-au-lait spots or other pigmentary cutaneous 
lesions that are associated with disorders of FGF-23 excess such as MAS or the epidermal nevus 
syndrome; angiofibromas or collagenomas that may be associated with MEN type 1; premature loss 
of deciduous teeth that occurs in hypophosphatasia; hallux valgus which is found in fibrodysplasia 
ossificans progressiva; alopecia that occurs in vitamin D-dependent rickets, type 2; brachydactyly 
which is found in PHP1a and PPHP; syndactyly that occurs in sclerosteosis types 1 and 2; torus 
palatinus which is found in disorders of high bone mass due to LRP5 or LRP6 mutations; or numerous 
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surgical scars which may reveal a past medical history of surgical treatments to remove endocrine 
tumours associated with the MEN syndromes [10, 20, 36, 39, 48, 50, 65, 67-69]. For some genetic 
bone diseases, a constellation of physical features indicates the category for diagnosis; e.g. rickets 
featuring craniotabes at birth and soon after a rachitic rosary (enlargement of the costochondral 
junctions) appearing during the first year of life [10]. Childhood-onset rickets causes bowed legs, 
short stature, flared wrists and ankles from metaphyseal widening [10]. Knock-knee deformities may 
occur instead of bowed legs if the rachitic disturbance occurs during the adolescent growth spurt [3]. 
In adults, skeletal deformation originating from metabolic bone disorders in childhood can cause 
substantial morbidity. Bowing of the lower limbs predisposes to osteoarthritis, especially affecting the 
knees. Without a complete physical examination, these important problems may go unnoticed.  
 
Family history 
Assessment of the family history is essential for establishing the mode of inheritance of monogenic 
metabolic bone diseases, and medical records from living or deceased affected family members may 
establish the diagnosis, guide prognostication, and indicate a safe and effective treatment [3]. In 
autosomal dominant disease, the affected person often has one affected parent, and the disease occurs 
in both sexes and is transmitted by either the father or mother. In autosomal recessive diseases, which 
can affect both sexes, the proband is born to parents who are usually asymptomatic “carriers” and 
sometimes related (i.e. consanguineous). In X-linked recessive diseases, usually only males are 
affected, parents are unaffected yet the mother is an asymptomatic carrier, and there is no male-to-
male transmission. In X-linked dominant diseases, both males and females can be affected, although 
the females are often more mildly and variably affected than males, and 50% of offspring (girls and 
boys) from an affected woman will have the disease, and 100% of the daughters but 0% of sons of an 
affected man will have the disease. In Y-linked diseases, only males are affected and unless 
representing a sporadic case they have an affected father (patrilineal inheritance) and all sons of an 
affected male will have the disease. Mitochondrial inherited disorders (non-Mendelian) can affect 
both sexes. However, these disorders are only transmitted by an affected mother (matrilineal 
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inheritance) in her egg mitochondrial DNA, and not through the paternal line in the sperm, as the 
small volume of sperm precludes them from contributing mitochondria to the zygote [3]. These 
patterns of inheritance may be complicated by: non-penetrance or variable expression in autosomal 
dominant disorders (e.g. in MEN1) [65]; imprinting whereby expression of an autosomal dominant 
disorder is conditioned by whether it is maternally or paternally transmitted (e.g. PHP1a versus 
PPHP) [39]; anticipation, whereby some dominant disorders become more severe (or have earlier 
onset) in successive generations; pseudo-dominant inheritance of autosomal recessive disorders 
reflecting repeated consanguineous marriages in successive generations; and mosaicism in which an 
individual has two or more populations of cells with different genotypes because of post-zygotic 
mutations during their development from a single fertilized egg (e.g. McCune-Albright syndrome). In 
the special circumstance of germline mosaicism within eggs or sperm arising from somatic mutation 
during gametogenesis, these may be confusion about the diagnosis and recurrence risk confusion 
because of seemingly unaffected parents having multiple affected offspring that would be consistent 
with autosomal recessive inheritance, but actually reflects an autosomal dominant disorder (e.g. OI 
type II) [70]. Hence, these inheritance patterns, which can help to diagnose a genetic disorder and 
identify individuals at risk, can come from a detailed family history [3]. 
 
Clinical utility of genetic investigations 
 
Establishing the genetic basis of a metabolic bone disease may aid diagnosis, treatment and 
prognostication; identify the need for screening of associated clinical features not initially apparent; 
enable appropriate genetic counselling and testing of first-degree asymptomatic relatives; and 
facilitate pre-conception and/or pre-natal genetic evaluation (Figure 2). Genetic testing may also aid 
risk profiling. For example, osteoporosis-associated SNPs have been reported to predict fracture risk 
in patients taking bisphosphonates [71], and other studies have identified potential genetic markers of 
bisphosphonate-induced osteonecrosis of the jaw [72].  
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For patients presenting with a likely genetic metabolic bone disease, several factors require 
consideration before organizing genetic testing (Figure 2). These include the phenotype of the patient, 
the likely mode of inheritance, the potential genetic aetiology (e.g., aneuploidy, copy number 
variation (CNV), or single gene defect), and availability of additional pedigree members (Figure 2). 
For example, DNA sequencing of ‘trios’ (i.e. both parents and the affected proband) may facilitate the 
identification of compound heterozygous or de novo mutations [73]. Selecting the most appropriate 
genetic test will increase the likelihood of achieving a genetic diagnosis. For example, direct DNA 
sequencing methods which detect nucleotide abnormalities (e.g. substitutions, micro-deletions and 
micro-insertions) that cause most monogenic metabolic bone disorders frequently do not detect whole 
or partial gene deletions that are associated with some monogenic syndromes, and are also not be 
optimal for identifying large chromosomal abnormalities (e.g. 22q11.2 microdeletion in DiGeorge 
syndrome), whose detection requires alternative approaches (Figure 2 and Table 2) [74]. For other 
monogenic disorders, it is also important to consider analysis of a panel of genes if genetic 
heterogeneity is likely (e.g. in FHH or OI) [9, 20]. Thus, it is important to emphasize that genetic 
testing which fails to identify an abnormality does not exclude a genetic disease, but rather may 
reflect: an alternative genetic aetiology to the one being tested; limitations of the employed genetic 
methodology (i.e. inadequate resolution or coverage); or incorrect assumptions regarding the clinical 
phenotype or mode of inheritance [3]. As a consequence, it may be necessary to undertake sequential 
or simultaneous genetic tests to ensure a complete evaluation, although such testing may be limited by 
cost and local availability. 
 
Types of genetic tests available to the clinician 
 
Cytogenetic and molecular cytogenetic analyses 
Karyotyping represents the initial test for major chromosomal abnormalities including aneuploidy or 
large insertions, deletions, duplications, inversions, or reciprocal translocations, but has a resolution 
limited to ~5-10Mb of DNA (Table 2) [74, 75]. It retains an important place in the diagnosis of Turner 
and Klinefelter syndrome, each of which may manifest a form of osteoporosis [76, 77]. Fluorescence 
 
This article is protected by copyright. All rights reserved. 
in-situ hybridization (FISH) employs DNA probes that hybridize to specific target regions, which 
allow the detection of specific chromosomal deletions, duplications, translocations or inversions 
(Table 2). The utility of FISH is limited to detecting abnormalities involving pre-determined genomic 
regions (e.g. detection of 22q11.2 deletion in DiGeorge syndrome). Multiplex-ligation dependent 
probe amplification (MLPA) detects complete or partial gene deletions by using a pool of custom-
designed probes to amplify specific genomic regions of interest (Table 2). MLPA is used in the 
diagnostic evaluation of monogenic disorders associated with such genetic alterations (e.g. MEN1) 
[78]. Modifications of the MLPA technique may also be used. For example, in establishing the 
diagnosis of pseudohypoparathyroidism type 1b (PHP1b), methylation-specific MLPA (MS-MLPA) 
may be employed to detect genetic (e.g. deletions) or epigenetic (e.g. altered patterns of methylation) 
abnormalities within the differentially methylated regions (DMRs) of the GNAS locus, although 
alternate methods such as CpG bisulphite pyrosequencing are frequently used to confirm the presence 
of specific methylation defects [79]. Microarray-comparative genomic hybridization (aCGH) is 
undertaken for the genome-wide detection of small chromosomal abnormalities (e.g. copy number 
variants (CNVs)) (Table 2) and is increasingly used as a first-line investigation for patients with 
multiple congenital abnormalities, which include skeletal manifestations and/or neurodevelopmental 
delay [80, 81]. However, it is important to note that all individuals harbor many small CNVs without 
discernable adverse impact on health, whilst several potentially pathogenic CNVs do not cause 
disease in all individuals (i.e. reduced penetrance). Finally, SNP arrays may detect CNVs as well as 
facilitating genome-wide genotyping (Table 2). For example, deletions spanning several adjacent 
SNPs included on the array may reveal loss of heterozygosity (LOH), whilst copy number gains (e.g. 
duplication) may be indicated by increased numbers of different genotypes [74]. SNP arrays may also 
help localize recessive disorders in the offspring of consanguineous parents by facilitating 
homozygosity mapping [82], whilst regions of LOH can also indicate uniparental isodisomy, which 
may be relevant to the diagnosis of imprinting disorders such as PHP1b [83, 84]. 
  
DNA sequence analysis 
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Sanger sequencing remains the gold standard for detecting DNA sequence variants due to the high 
accuracy of the DNA polymerase (i.e. base accuracy of >99.99%) employed during DNA 
amplification [41, 85]. However, it remains labour intensive and is typically reserved for disorders 
with low genetic heterogeneity (e.g. single- or pauci-gene disorders), an example being 
hypophosphatasia caused only by TNSALP/ALPL mutations [86]. Single gene testing by Sanger 
sequencing is increasingly being replaced by next-generation sequencing (NGS) approaches, which 
facilitates the simultaneous sequencing of large amounts of genetic material. Such NGS methodology 
has provided a paradigm shift in the investigation and diagnosis of genetic disease. Currently, the 
three most widely employed uses of NGS are: whole genome sequencing (WGS); whole exome 
sequencing (WES), and disease-targeted gene panel sequencing (Table 2). WGS determines the DNA 
sequence of the entire genome including coding and non-coding regions, and can identify SNVs, 
small insertions or deletions (‘indels’), and CNVs [3]. In contrast, WES analyses the 1-2% of the 
genome that encodes the ~20,000 protein-coding genes (i.e. the ‘exome’), which are expected to 
harbor most disease-associated mutations [3]. WES has been the mainstay of highly successful 
disease-gene discovery studies over the past decade, resulting in the identification of several genes 
responsible for metabolic bone disorders (e.g. WNT1 mutations as causes of osteoporosis and OI [19]; 
SFRP4 mutations in Pyle’s disease [54]; AP2 mutations in FHH type 3 [33]; PLS3 mutations in X-
linked osteoporosis [18]; BMP1 mutations causing increased BMD and recurrent fractures [87]; and 
CYP3A4 mutations in vitamin D-dependent rickets, type 3 [88]).
 
Disease-targeted sequencing 
represents the most widely utilized NGS method in clinical practice, as it can be designed to 
simultaneously analyze large collections of genes (e.g. <10 to >150 genes) associated with a specific 
disorder [41, 85, 89]. Such NGS disease-targeted panels have been established for genetically 
heterogeneous disorders including OI and other skeletal disorders, as well as for hypophosphataemic 
rickets and calcium-sensing disorders [90-92]. 
 
Genetic tests to detect mosaicism 
Some metabolic bone disorders only manifest as somatic mosaicism (e.g. GNAS mutations in 
McCune-Albright syndrome) [67]. However, other conditions (e.g. OI type II) may also rarely occur 
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as germline mosaicism, arising from somatic mutation during gametogenesis, and may cause 
diagnostic confusion. In this setting, apparently unaffected parents (with one carrying the mutation 
limited to their gametes) may give rise to more than one affected child, suggesting possible autosomal 
recessive inheritance, in contrast to the underlying autosomal dominant inheritance pattern
 
[93].
 
Detection of mosaicism has been enhanced by improved genome-wide testing strategies (e.g. aCGH, 
SNP arrays, droplet digital PCR and NGS approaches), which can provide sensitive methods for the 
detection of low-level mosaicism (e.g. 5% for SNP array) [70, 94, 95]. However, choosing the optimal 
test depends on the clinical phenotype, the type of mutation suspected (e.g. SNV, CNV, aneuploidy), 
the likely extent of mosaicism, and its tissue distribution. Typically, circulating lymphocyte DNA will 
suffice, but analysis of other affected tissues may be required (e.g. fibroblasts or bone) [96, 97]. 
 
Genetic Tests for Prenatal diagnosis 
Pre-natal genetic testing may be undertaken at pre-implantation or pre-natal stages, and has been used 
to detect severe skeletal disorders such as perinatal lethal OI [98]. Pre-implantation genetic diagnosis 
(PGD) uses a single cell taken from the developing embryo several days after in vitro fertilization 
(IVF) to detect chromosomal abnormalities or single gene defects, thereby allowing selection of the 
unaffected embryos for implantation [99]. In contrast, pre-natal genetic testing is used once pregnancy 
is established to identify fetuses at risk of genetic disease [99]. Typically, this involves invasive 
methods such as chorionic villous sampling (CVS) or amniocentesis to obtain cells for genetic 
evaluation [99]. This may include karyotyping for the detection of aneuploidy, FISH or aCGH to 
identify smaller chromosomal abnormalities or DNA sequencing to identify single gene defects 
associated with monogenic disease. Recent progress in the detection of cell-free circulating fetal DNA 
in the maternal circulation (e.g. after ~10 weeks gestation) now offers the potential for non-invasive 
prenatal genetic diagnosis (NIPD) and/or testing (NIPT) [100]. Thus, a maternal blood sample may 
allow screening for aneuploidy and fetal sex determination, which is important for X-linked disorders, 
and may also be used to detect monogenic disorders; however, this is limited to paternally inherited 
mutations or those arising de novo, as the sample may contain maternal cell-free DNA, and hence the 
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detected abnormality cannot be reliably assigned to the fetus as the methodology cannot distinguish 
between fetal and “contaminating” maternal DNA in the sample [100].  
 
Data interpretation and incidental findings 
The advent of high-content genetic testing employing NGS approaches has revolutionized the 
investigation and diagnosis of genetic disease. However, such approaches may also present clinical 
and ethical challenges [101]. For example, the simultaneous sequencing of large numbers of genes 
(e.g. disease-targeted gene panels, WES and WGS) inevitably identifies variants of uncertain 
significance (VUS), whose relevance to the clinical phenotype is ambiguous [102, 103]. Indeed, the 
methods employed to assess variant effects are frequently imprecise leading to inaccurate 
interpretation, although the provision of recent large-scale population level sequence databases 
facilitate improved estimates of variant pathogenicity and penetrance [104, 105]. In addition, high-
content genetic testing may identify clinically relevant genetic abnormalities unrelated to the 
phenotype under investigation (i.e. incidental findings (IFs)) and these may have important health 
implications for the patient and their family. Hence, the possibility of identifying ambiguous or 
incidental results should be part of the informed consent prior to genetic testing (Figure 2).  
 
Conclusion 
 
Many metabolic bone diseases have a genetic basis, which may be a germline single gene abnormality 
(i.e. a monogenic or Mendelian disorder), a somatic single gene defect (i.e. a post-zygotic mosaic 
disorder), or involve several genetic variants (i.e. oligogenic or polygenic disorders). Recognition of 
these heritable disorders is clinically important, as it can facilitate relevant and timely investigation 
and treatment for the patients and families. Recent advances in genetics and DNA sequencing 
methods have resulted in new ways to detect genetic abnormalities. Therefore, it is increasingly 
important for the clinician to gain an appreciation of these complex genetic tests and to combine this 
with the fundamental skills of history taking and physical examination to ensure they are used for the 
benefit of patients. 
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Table 1. Examples of monogenic metabolic bone disorders, modes of inheritance and genetic 
aetiology 
 
Mode of inheritance/ Disease Gene(s) Chromosomal 
location 
References 
Autosomal Dominant    
Osteogenesis imperfecta (OI), types I-IV COL1A1, COL1A2 17q21.33, 7q21.3 [20] 
Osteogenesis imperfecta (OI), type V IFITM5 11p15.5 [23, 24] 
Autosomal dominant hypophosphataemic rickets FGF23 12p13.32 [25] 
Autosomal dominant high bone mass, type 1 LRP5 11q13.2 [47] 
Autosomal dominant high bone mass, type 2 LRP6 12p13.2 [48] 
Early-onset osteoporosis WNT1 12q13.12 [19] 
Familial hypocalciuric hypercalcaemia (FHH), 
types 1-3 
CASR, GNA11, AP2S1 3q21.1, 19p13.3, 
19q13.3 
[31-33] 
Autosomal dominant hypocalcaemia (ADH), 
types 1-2 
CASR, GNA11 3q21.1, 19p13.3 [32, 37] 
Familial expansile osteolysis TNFRSF11A 18q21.33 [34, 35] 
Hypophosphatasia TNSALP/ALPL 1p36.12 [36] 
Vitamin D-dependent rickets, type 3 CYP3A4 7q22.1 [88] 
Pseudohypoparathyroidism, type 1a (PHP1a)* GNAS 20q13.3 [39] 
Pseudopseudohypoparathyroidism (PPHP)* GNAS 20q13.3 [39] 
Pseudohypoparathyroidism, type 1b (PHP1b)* GNAS, NESP55, STX16 20q13.3 [39] 
    
Autosomal Recessive    
Osteogenesis imperfecta (OI), type VI SERPINF1 17p13.3 [106] 
Osteogenesis imperfecta (OI), type VII CRTAP 3p22.3 [21] 
Osteogenesis imperfecta (OI), type VIII P3H1/LEPRE1 1p34.2 [107] 
Osteogenesis imperfecta (OI), type XV WNT1 12q13.12 [19] 
Hypophosphatasia TNSALP/ALPL 1p36.12 [36] 
Neonatal severe hyperparathyroidism (NSHPT) CASR 3q21.1 [31] 
Vitamin D-dependent rickets, type 1 CYP27B1 12q14.1 [10] 
Vitamin D-dependent rickets, type 2 VDR 12q13.11 [10] 
Autosomal recessive hypophosphataemic rickets DMP1, ENPP1 4q22.1, 6q23.2 [27, 28] 
Hereditary hypophosphataemic rickets with 
hypercalciuria 
SLC34A3 9q34.3 [29, 30] 
Osteoporosis-pseudoglioma syndrome LRP5 11q13.2 [46] 
Sclerosteosis, type 1 SOST 17q21.31 [49] 
Sclerosteosis, type 2 LRP4 11p11.2 [50] 
Pyle’s disease SFRP4 7p14.1 [54] 
Juvenile Paget disease TNFRSF11B 8q24.12 [108] 
    
X-linked Dominant    
X-linked hypophosphatemic (XLH) rickets PHEX Xp22.11 [26] 
    
X-linked recessive    
X-linked osteoporosis PLS3 Xq23 [18] 
Dent disease, type 1 CLCN5 Xp11.23 [11] 
    
Mitochondrial    
Mitochondrial encephalomyopathy with lactic 
acidosis and stoke-like episodes (MELAS) 
Mitochondrial genome - [13] 
Kearns-Sayre syndrome Mitochondrial genome - [14] 
    
Mosaicism    
McCune-Albright syndrome (polyostotic fibrous 
dysplasia)* 
GNAS 20q13.3 [15] 
Osteogenesis imperfecta (OI)§ COL1A1/COL1A2 17q21.33, 7q21.3  
 
*Parentally imprinted. 
§Autosomal disorder manifesting as post-zygotic somatic mosaicism in the developing fetus, or arising from germline 
mosaicism in an apparently unaffected parent. 
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Table 2: Examples of genetic tests, their molecular resolution and utility 
Genetic Test Resolution Abnormalities detected Additional Notes 
Detection of Chromosomal Abnormalities including Copy Number Variations (CNVs) 
Karyotype: G-banding (trypsin-Giemsa 
staining) 
5-10Mb Aneuploidy  
Large chromosomal deletions, duplications, 
translocations, inversions, insertions 
Limited resolution 
Requirement to study many cells to detect mosaicism 
 
Fluorescence in situ hybridization 
(FISH) 
50kb - 2Mb (dependent on size 
of probes employed) 
Structural chromosomal abnormalities (e.g. 
microdeletions, translocations)  
Labour-intensive 
Low resolution limits its use 
Unsuitable where unknown genetic aetiology 
Multiplex-ligation probe amplification Probe dependent 
50-70 nucleotides 
Single exon deletion or 
duplication possible 
Copy number variations (CNVs) including 
(partial) gene deletions or duplications 
 
Low cost, technically simple method 
Simultaneous evaluation of multiple genomic regions  
Not suitable for genome-wide approaches  
Not suitable for analysis of single cells 
Array Comparative genomic 
hybridization (aCGH) 
10Kb (high resolution) 
1Mb (low resolution) 
(Dependent on probes set)  
Genome-wide copy number variations 
(CNVs) 
 
Inability to detect balanced translocations 
Useful for detection of low level mosaicism 
 
Single Nucleotide Polymorphism (SNP) 
array 
~50-400Kb 
(Dependent on probe set) 
Genome-wide detection of SNP genotypes 
Copy Number Variations (CNVs) 
 
Inability to detect balanced translocation 
Useful for detection of low level mosaicism 
Detection of copy number neutral regions or absence of 
heterozygosity (i.e. due to uniparental disomy) 
Detection of Monogenic Disorders (and Copy Number Variations (CNVs)) 
First Generation Sequencing (Sanger)     
Single gene test Single nucleotide  
(exonic regions and intron/exon 
boundaries of candidate gene) 
Single nucleotide variants (SNVs) 
Small insertions of deletions (‘indels’) 
Relative high cost/base 
May miss large deletions/duplications 
Unsuitable where unknown genetic aetiology 
Next Generation Sequencing     
Disease-targeted gene panels Single nucleotide 
(exonic regions and intron/exon 
boundaries of candidate genes) 
Single nucleotide variants (SNVs) 
Small insertions of deletions (‘indels’) 
May lack complete coverage of exomic regions (may require 
Sanger sequencing to fill in ‘gaps’) 
Increased likelihood of identifying variants of uncertain 
significance (VUS) as number of genes increases 
Unsuitable where unknown genetic aetiology 
Whole exome sequencing (WES) Single nucleotide 
(all exonic regions and 
intron/exon boundaries ) 
Single nucleotide variants (SNVs) 
*Small insertions of deletions (‘indels’)  
Copy Number Variations (CNVs) 
 
Not all exons may be covered/captured 
Difficulties with GC-rich regions and presence of homologous 
regions/pseudogenes 
*Small indels may not be captured 
Bioinformatic expertise required for data analysis 
High likelihood of incidental findings and VUSs 
Detection of CNVs requires additional data analysis (i.e. loss of 
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heterozygosity mapping across exonic regions) 
Suitable for disease associated gene-discovery 
Whole Genome Sequencing (WGS) Single nucleotide Single nucleotide variants (SNVs) 
Small insertions of deletions (‘indels’) 
Copy Number Variations (CNVs) 
(Translocations/rearrangements) 
 
Relative high cost 
Large data sets generated and complex data analysis requiring 
bioinformatic expertise  
High likelihood of incidental findings and VUSs 
CNV analysis possible but may present specific challenges 
Suitable for disease associated gene-discovery 
Abbreviations: CNVs, copy number variants; FISH, fluorescence in-situ hybridization; Ifs, incidental findings; LOH, loss of heterozygosity; WES, whole exome sequencing; 
WGS, whole genome sequencing. Adapted from Genetics of Bone Biology and Skeletal Disease (2018). Edited by Thakker, Whyte, Eisman, Igarashi, Second Edition. 
Academic Press. p.14 [3].  
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Figure 1. Schematic representation of Wnt signalling pathway components reported to be mutated in 
disorders of bone development and skeletal homeostasis. Activation of the canonical Wnt pathway 
increases bone mass, and this is mediated by the binding of extracellular Wnt ligands (dark green) to a 
transmembrane receptor complex comprising the Wnt co-receptor LRP5 or LRP6 (LRP5/6, light blue) 
and a member of the frizzled (FZD) family (dark blue). In contrast, inhibition of the canonical Wnt 
pathway decreases bone mass [44, 45]. This inhibition is mediated by extracellular factors such as 
sclerostin (SOST, orange) and Dickkopf-related protein 1 (DKK1, yellow), which bind to the LRP5/6 
co-receptor thereby preventing activation by Wnt ligands, as well as recruiting inhibitory 
transmembrane proteins such as: LRP4, which is a SOST-interacting protein (light green); and the 
Kremen proteins (pink), which are high-affinity DKK1 receptors that functionally cooperate with 
DKK1 to decrease Wnt signalling [109]. Secreted-frizzled-related proteins (SFRPs, purple) also 
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inhibit the canonical Wnt pathway by sequestering Wnt ligands. The importance of the canonical Wnt 
pathway for the regulation of bone mass has been highlighted by loss-of-function mutations affecting 
SOST and LRP4, and by gain-of-function mutations of LRP5 and LRP6, which lead to the disorder 
called high bone mass [47, 49, 51, 110]; and also by loss-of-function mutations of LRP5 and the Wnt1 
ligand, which lead to monogenic osteoporosis disorders [19, 46]. 
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Figure 2. Flowchart outlining considerations for genetic testing in patients with metabolic bone 
disease. 
